Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.

Documentation is especially important for nurse practitioners in cancer research and can lead to improved patient recruitment ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after ...

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy. Lerociclib plus fulvestrant demonstrated a ...

Seth Eisenberg, ASN, RN, OCN, BMTCN discussed the results of a real-world trial of Splashblocker, a toilet seat cover ...

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal ant ...